Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_3
6
100%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
6(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 36 (100.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
completedphase_3

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
completedphase_3

A Study Designed to Evaluate Tear Production

NCT06544707
completedphase_3

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111
completedphase_3

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06544694Phase 3

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Completed
NCT06660290Phase 3

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Completed
NCT06544707Phase 3

A Study Designed to Evaluate Tear Production

Completed
NCT05493111Phase 3

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

Completed
NCT05360966Phase 3

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Completed
NCT05285644Phase 3

Study Evaluating the Safety and Efficacy of AR-15512

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6